Interestingly, EGFR inhibition did not improve the anti-cancer effect of paclitaxel, a major chemo-therapeutic drug for the clinical treatment of BLBC (Fig. 6c), suggesting that EGFR inhibition only targets specific feedback signalling. This evidence concerns the gene EGFR and cancer.